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Abstract
Since in vitro studies and a preliminary clinical report suggested the efficacy of chloroquine for COVID-19-associated 
pneumonia, there is increasing interest in this old antimalarial drug. In this article, we discuss the pharmacokinetics and 
safety of chloroquine that should be considered in light of use in SARS-CoV-2 infections. Chloroquine is well absorbed 
and distributes extensively resulting in a large volume of distribution with an apparent and terminal half-life of 1.6 days 
and 2 weeks, respectively. Chloroquine is metabolized by cytochrome P450 and renal clearance is responsible for one third 
of total clearance. The lack of reliable information on target concentrations or doses for COVID-19 implies that for both 
adults and children, doses that proved effective and safe in malaria should be considered, such as ‘loading doses’ in adults 
(30 mg/kg over 48 h) and children (70 mg/kg over 5 days), which reported good tolerability. Here, plasma concentrations 
were < 2.5 μmol/L, which is associated with (minor) toxicity. While the influence of renal dysfunction, critical illness, or 
obesity seems small, in critically ill patients, reduced absorption may be anticipated. Clinical experience has shown that 
chloroquine has a narrow safety margin, as three times the adult therapeutic dosage for malaria can be lethal when given as 
a single dose. Although infrequent, poisoning in children is extremely dangerous where one to two tablets can potentially be 
fatal. In conclusion, the pharmacokinetic and safety properties of chloroquine suggest that chloroquine can be used safely 
for an acute virus infection, under corrected QT monitoring, but also that the safety margin is small, particularly in children.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-020-00891 -1) contains 
supplementary material, which is available to authorized users.
 * Catherijne A. J. Knibbe 
 c.knibbe@antoniusziekenhuis.nl
1 Pediatric Pharmacology and Pharmacometrics Research 
Center, University of Basel Children’s Hospital, Basel, 
Switzerland
2 Department of Systems Biomedicine and Pharmacology, 
Leiden Academic Centre for Drug Research, Leiden 
University, Leiden, The Netherlands
3 Department of Clinical Pharmacy, St. Antonius Hospital, 
Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands
4 Division of Clinical Pharmacology, Children’s National 
Hospital, Washington, DC, USA
1 Introduction
There is an increasing interest in chloroquine for the treat-
ment of COVID-19-associated pneumonia since in vitro 
studies suggested the inhibition of SARS-CoV-2 [1, 2], and 
Gao et al. issued a statement indicating the superiority of 
this almost 90-year-old drug compared with control treat-
ment in more than 100 SARS-CoV-2-infected patients [3]. 
Introduced in the 1940s, as an antimalarial drug, chloro-
quine increases the pH of intracellular organelles such as 
endosomes and lysosomes essential for membrane fusion. It 
also appears to interfere with terminal glycosylation of the 
cellular receptor, angiotensin-converting enzyme 2, which 
may influence the virus-receptor binding and enhance its 
antiviral properties [4].
In the past, the growth of different viruses, including 
SARS-CoV, was reported to be inhibited in cell cultures 
by chloroquine and hydroxychloroquine. However, despite 
extensive preclinical and clinical studies, no single acute 
virus infection has been successfully treated by chloroquine 
in humans, with even a bad long-term outcome reported in 
some clinical trials [5]. In light of the current SARS-CoV-2 
pandemic, results of well-designed placebo-controlled clini-
cal studies with chloroquine vs standard of care with rel-
evant clinical endpoints are urgently needed. In the mean-
time, chloroquine has become one of the main therapeutics 
in treating COVID-19-associated pneumonia because of its 
availability, known safety record, and relatively low cost.
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Awaiting further evidence of its potential use in the treat-
ment of COVID-19-associated pneumonia, we discuss here 
the unique pharmacokinetic and safety properties of chlo-
roquine retrieved from preclinical and clinical experience 
with this drug for malaria and other diseases. These should 
be considered when treating COVID-19-associated pneu-
monia with chloroquine, or when designing or interpreting 
results from clinical studies on the effects of chloroquine in 
these patients.
2  General Pharmacokinetic Properties
Oral absorption of chloroquine is nearly complete with an 
estimated bioavailability of 78% and 89% for the oral solu-
tion and tablet, respectively [6, 7]. When administered with 
food, the time to peak concentration is similar, but plasma 
concentrations and area under the curve are reported to be 
higher, even though the effect of food seems to be subject to 
large inter-individual variability [8]. Magnesium-containing 
antacids can lower the absorption of chloroquine [9].
After absorption, chloroquine extensively distributes 
across all tissues resulting in a very large volume of distri-
bution of 200 L/kg which, combined with a slow elimina-
tion, results in a terminal half-life reported to vary between 
days and weeks depending on the sampling time used in the 
study [7, 10, 11]. The apparent half-life, however, is much 
shorter at 1.6 days [12]. Nonetheless, even after a single 
dose in humans, chloroquine can be measured in plasma and 
urine at weeks or even over a year after dosing as a result of 
redistribution from the tissue compartments [13]. Chloro-
quine is actively transported into the cell’s lysosomes (or the 
malarial parasite’s acidic food vacuole), where it is ‘trapped’ 
by protonation owing to the organelle’s acidic environment 
[14]. Preclinical experiments show that, compared with 
plasma concentrations, concentrations in red blood cells are 
7.3–10.4 times higher, in the heart 6.8–184 times higher, and 
in lung tissue 11.8–450 times higher when measured over 
a period of 168 h after a single dose [15]. The variation in 
these factors within the same tissue is explained by a slower 
decrease in tissue concentrations compared with plasma, 
leading to the highest differences at the latest time point 
(i.e., 168 h) after this single dose. Similarly, concentrations 
in whole blood are reported to be between 2.5, 3.7, or even 
8 times higher compared with plasma concentrations [1, 16, 
17], which should be considered when comparing results of 
different clinical reports with some studies reporting chlo-
roquine concentrations in whole blood [18] or dried blood 
spot samples [19], while other studies report plasma con-
centrations [20]. Furthermore, concentrations measured in 
serum have been reported to be higher than those measured 
in plasma because platelet-bound chloroquine may release 
during clot formation [21]. Protein binding of chloroquine 
is irrelevant [22].
Chloroquine pharmacokinetics are linear when dosed 
between 2 and 15 mg/kg [23] and it is metabolized exten-
sively by N-dealkylation in the liver, catalyzed by several 
members of the cytochrome P450 (CYP) family, to deseth-
ylchloroquine and bisdesethylchloroquine. Desethylchloro-
quine is considered an active metabolite against Plasmodium 
falciparum, albeit less effective than chloroquine [14], and 
was, similar to chloroquine, reported to be active against 
the Zika virus [24]. However, no data are available on the 
effectiveness of desethylchloroquine in SARS-CoV-2. Bisde-
sethylchloroquine is reported to be a toxic metabolite asso-
ciated with heart failure due to long-term treatment with 
chloroquine [25]. Involved CYPs, based on human liver 
microsome studies, include CYP1A2, CYP2C8, CYP2C19, 
CYP2D6, and CYP3A4/5 with CYP2C8 and CYP3A4/5 as 
major enzymes responsible for the formation of desethyl-
chloroquine [26]. Although pharmacokinetic interactions 
can hence be expected in combination with CYP-inhibiting 
drugs [9], chloroquine is more infamous for its role as a 
perpetrator drug in several interactions. For example, higher 
concentrations of cyclosporine [27, 28] and potentially of 
P-glycoprotein substrates such as digoxin [9], dabigatran, 
or edoxaban have been described, even though digoxin 
and chloroquine were combined successfully in a case of 
Key Points 
Although interest in the use of chloroquine for the treat-
ment of COVID-19-associated pneumonia has recently 
increased because of in vitro efficacy studies and a 
preliminary clinical report, reliable information on chlo-
roquine including doses or target concentrations for this 
application is lacking
Until information of high-quality studies becomes avail-
able, we suggest considering dose regimens that have 
proven to be effective and safe in other diseases, such as 
malaria, to guide chloroquine dosing in SARS-CoV-2 
infections in adults and children
Given the unique pharmacokinetic profile of chloroquine 
and data from several pharmacokinetic studies, no large 
impact of renal dysfunction, critical illness, or obesity is 
expected, although in critically ill patients, drug absorp-
tion might be hampered
Although chloroquine seems well tolerated in thera-
peutic dose regimens under corrected QT monitoring, 
it has been shown to be possibly lethal in short-term 
intoxications, especially in children, for which caution is 
warranted
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myocarditis as a result of malaria infection [29]. Renal clear-
ance was found to constitute 57% of total body clearance 
after a single dose [7] vs 33% in steady state [30]. In total, 
55% of the dose is recovered in urine of which chloroquine 
constitutes 70% of the total amount recovered, resulting in 
an unchanged elimination of chloroquine of 38% [30]. Given 
the extreme affinity of chloroquine for tissues, redistribution 
from the periphery to the blood compartment is the rate-
limiting step for elimination of the drug from the human 
body [7].
Chloroquine is clinically administered as a racemic mix-
ture, with similar pharmacodynamic properties, but slightly 
differrent pharmacokinetics between both enantiomeres 
being reported, the latter mostly regarding protein bind-
ing and clearance  [31]. As the clinical implications are not 
well established to date, and most (pharmacokinetic) stud-
ies report total concentrations of chloroquine only (i.e., the 
sum of both enantiomers), we focus on the total chloroquine 
concentration in this article.
3  Safety Aspects to Consider in Acute Viral 
Infections
For the use of chloroquine in an acute viral infection such as 
COVID-19-associated pneumonia, early achievement of ‘tar-
get’ concentrations at the site of action seems a prerequisite 
for its potential efficacy but also poses a safety risk. More 
specifically, to achieve these concentrations early after the 
start of treatment, for this drug with extensive distribution 
and slow elimination, high loading dosages are required. 
Hence, information on the safety of these high dosages is 
paramount.
It is known from reports on chloroquine overdose that it 
can cause severe life-threatening toxicity, with ingestion of 
a dose of 5 g in adults being almost universally lethal when 
untreated [32]. Moreover, among persons ingesting 2.25 g or 
more, corresponding to only three times a therapeutic dose 
of 10 mg/kg for a typical adult patient, an overall mortality 
rate of 19% was reported [33]. Acute toxicity in overdose 
occurs very rapidly with gastrointestinal and neurological 
symptoms within the first hour, rapidly followed by impaired 
ventricular conduction, wide QRS complexes > 100 ms, 
corrected QT (QTc) prolongation, hypotension, and severe 
hypokalemia secondary to intracellular potassium shifting, 
resulting in an increased risk of ventricular dysrhythmias 
(i.e., torsades de pointes). Aggressive treatment consisting of 
a combination of early mechanical ventilation, administra-
tion of diazepam and epinephrine together with potassium 
correction may be effective, also in cases with chloroquine 
doses above 5 g [32]. This treatment protocol was even suc-
cessful in a massive overdose where a plasma concentration 
of 47 μmol/L was measured [34]. In this case, treatment 
could be gradually discontinued on the third day with 
extubation 66 h after admission at which time the plasma 
chloroquine concentration was 2.4  μmol/L [34]. These 
cases illustrate that toxic effects rarely last more than 24 h, 
despite a terminal elimination half-life of 14 days. This can 
be explained by the short apparent half-life of 1.6 days due 
to rapid distribution of chloroquine from the central com-
partment with extensive tissue binding.
Over the years, several (whole blood) chloroquine con-
centrations have been proposed as a cut-off point for toxicity 
in acute intoxications. A fatal outcome was reported above 
whole blood concentrations of 25 μmol/L [32, 34]. However, 
others refer to Stead and Moffat who reported fatal or toxic 
whole blood concentrations of 7 and 2.3 μmol/L, respec-
tively [35], or to Jaeger et al. who report serum concentra-
tions of 7.8 and 15.5 μmol/L for moderate and severe intoxi-
cations [36]. As it is particularly difficult in a short-term 
dosage to make direct comparisons between blood, serum, 
and plasma concentrations with reported correction factors 
between whole blood and plasma varying between 2.5 and 8 
[1, 16, 17], it seems that these concentrations can currently 
not be used as a guide [34]. Perhaps the earlier mentioned 
plasma concentration of 2.4 μmol/L, measured around extu-
bation in a patient 66 h after a massive overdose could be 
considered as a boundary for (minor) toxicity [34]. A similar 
threshold was found with long-term use of chloroquine in 
rheumatoid arthritis, where in 80% of patients with serum 
concentrations above 0.8 μg/mL (or 2.5 μmol/L) side effects 
such as visual and central nervous system disturbances were 
reported, whereas when concentrations were lower than 0.4 
μg/mL (or 1.3 μmol/L), there were no side effects. Except 
for maculopathy in one patient, all side effects reversed on 
discontinuation of the drug [37]. Furthermore, after intrave-
nous administration of a 300-mg dose, side effects such as 
difficulties with swallowing, fatigue and ocular side effects 
such as diplopia or problems with accommodation occurred 
within the first 45 min of dosing, when peak plasma concen-
trations of 837 ng/mL (corresponding to 2.61 μmol/L) were 
reached [7]. No adverse reactions were observed after oral 
doses of 300 mg, yielding median peak concentrations of 
73 ng/mL (corresponding to 0.23 μmol/L). Another study 
reported hypotension as a main adverse effect after paren-
teral chloroquine [6], which did not occur when chloroquine 
was administered over 1 h. From these observations, it seems 
that during this initial phase after intravenous administra-
tion, chloroquine needs to be distributed from the relatively 
small central blood compartment resulting in transient high 
concentrations and a risk for acute toxicity, which is only 
observed for a very short time because of rapid distribution 
into tissues.
Regarding toxicity in children, it is known from many 
reports that poisoning in children, although infrequent, 
is extremely dangerous because children are particularly 
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sensitive to chloroquine toxicity [38]. With (accidental) 
overdose, most children become symptomatic within 30 min 
after ingestion and may die within the first 3 h even with 
aggressive treatment. Ingestion of only one tablet of 300 mg 
was fatal for a 12-month-old infant with a chloroquine serum 
concentration of 4.4 mg/L (13.6 μmol/L) [39]. A 13-year-
old boy who took approximately 750 mg of chloroquine 
developed ventricular fibrillation at a plasma concentration 
of only 4.2 μmol/L [40]. Another case report presented a 
3-year-old child who died after taking two 150-mg base tab-
lets of chloroquine [41]. From these case reports, it seems 
that even though patients’ serum concentrations and clini-
cal findings correlate well with adult findings, the outcome 
differs greatly between adults and children. These pediatric 
cases further underscore that chloroquine should be kept 
away from children and patients unfamiliar with its use.
A pharmacokinetic model developed under therapeutic 
use of chloroquine such as the Zhao et al. model [20] cannot 
be used for the prediction of concentrations with overdose 
in adults or children (see Electronic Supplementary Mate-
rial [ESM]). This observation suggests that after overdose, 
redistribution of the very high concentrations in the central 
compartment to the tissue compartments is not similar to 
redistribution with tissue binding after therapeutic dosages. 
This might be explained by lysosomal trapping of chloro-
quine, which is an active process that is probably saturable 
in the setting of a massive overdose [14].
4  Can We Define a Dose or Target Plasma 
Concentration of Chloroquine for Treating 
COVID‑19‑Associated Pneumonia?
In vitro EC50 values for chloroquine in SARS-CoV-2 were 
reported between 1.13 [2] and 5.47 μM [1]. For SARS-CoV, 
the IC50 value was 8.8 μM with as little as 0.1–1 μM of 
chloroquine reducing the infection by 50% and up to 90–94% 
inhibition with 33–100 μM concentrations [42]. In this 
respect, results of in vitro EC50 values are known to vary 
between cell types with the virus being able to adapt in cell 
culture [1]. Moreover, in vitro studies have not shown to be 
very predictive for the animal or human situation [5].
It is unknown how to relate in vitro values to the above-
reported extreme differences in concentrations between red 
blood cells, plasma, and the presumed target tissue, like for 
instance the lung in pneumonia related to COVID-19. Given 
the extensive distribution to tissue, plasma concentrations 
may or may not be of predictive value as an efficacy meas-
ure. For most antibacterial drugs, concentrations in plasma 
correlate with unbound concentrations in the interstitial fluid 
and are therefore considered best predictors for efficacy [43]. 
However, this assumption has been challenged by others, 
promoting the direct measurement of the free fraction of 
antibiotics in the extracellular fluid directly via microdialysis 
[44]. Measuring drug concentrations in tissue homogenates 
is currently widely abandoned, as this approach does not 
take into account that tissues consist of multiple compart-
ments over which the drug does not necessarily distribute 
equally [44, 45]. Second, the ratio between plasma and tissue 
concentrations varies over time, making multiple measure-
ments per individual necessary, which gives practical and 
ethical problems [45]. To our knowledge, only one study 
assessed the lung penetration of chloroquine, which was 
performed in rats by measuring tissue homogenate [15]. 
These data were recently incorporated in a COVID-19 physi-
ologically based pharmacokinetic model by Yao et al. to 
simulate lung concentrations in relation to the EC50 values 
found in vitro [1]. In addition to the major drawbacks regard-
ing concentrations in tissue homogenates, it also remains 
unclear what the particular site of action of chloroquine is in 
COVID-19-associated pneumonia. A parallel can be made 
to azithromycin, another basic drug that has been shown 
to accumulate in lung macrophages and, by being slowly 
released into extracellular fluid, was highly effective in erad-
icating Haemophilus influenzae from the lung in a mouse 
model [46]. However, it is unclear whether these principles 
also apply to chloroquine and its antiviral activity. Therefore, 
we argue that to date we do not have enough information 
yet to identify whether concentrations in lung tissue from 
homogenates or concentrations in extracellular fluid or in 
lysosomes would be the target for a chloroquine dose strat-
egy for COVID-19-associated pneumonia. As such, until 
more knowledge is obtained on in vivo target exposures, we 
should focus on dosages that have shown to be safe in other 
diseases, such as malaria.
5  What can We Learn from Chloroquine 
Studies Performed in Adults and Children 
with Malaria
In view of the small differences between effective and toxic 
doses, it seems that for COVID-19-associated pneumonia, 
advantage should be taken of (safety) experience obtained 
for the treatment of malaria where high loading doses are 
given over 1–3 days in adults and children. In these studies, 
it has been shown that higher initial doses at the start of 
treatment may be beneficial and are safe. In a clinical study 
by Pussard et al., a high dose (30 mg/kg over 2 days: 10 mg/
kg at 0 h, 5 mg/kg at 6 h, 12 h, 24 h, and 36 h) was reported 
to result in a reduced time required for a 50% decrease in the 
initial parasitemia (14.3 ± 1.6 h vs 35.5 ± 5.4 h, p < 0.01) and 
more rapidly obtained negative blood smears (50.8 ± 3.7 vs 
72 ± 8.7 h) compared with a standard dose (25 mg/kg over 
3 days: 10 mg/kg at 0 h, 24 h, and 5 mg/kg at 48 h) [47]. As 
Pussard et al. [47] reported that this ‘loading dose’ of 30 mg/
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kg given over 48 h was well tolerated, this seems a dosing 
regimen that deserves attention when studying the effects 
of chloroquine in SARS-CoV-2. Using this regimen, higher 
concentrations earlier in treatment may be obtained com-
pared to other proposed dosages for SARS-CoV-2. Figure 1 
shows concentration–time profiles that can be expected in 
a standard individual of 70 kg with this high loading dose 
over 48 h according to Pussard et al. [47] (panel B) com-
pared to one of the currently proposed dosages for COVID-
19-associated pneumonia (panel A), which is a fixed dose 
of 3300 mg over 5 days with 600 mg and 300 mg on the 
first day (see ESM for details). To generate these plots, the 
pharmacokinetic model published by Zhao et al. [20] was 
used after it had been extensively evaluated for its predictive 
performance with observations from a large number of other 
pharmacokinetic studies including studies in children (from 
0.5 to 18 years of age) and adults with renal dysfunction 
[10, 18, 19, 47–52] (see ESM for details about the model 
and simulations). In this figure, it can be seen that the high 
loading dose schedule of Pussard et al. [47] may lead to 
higher chloroquine plasma concentrations at the beginning 
of therapy without increasing the maximum concentration 
compared to the standard dose for individuals of 70 kg with-
out renal dysfunction.
Similarly, in 4- to 8-year-old children with malaria, high-
dose chloroquine (50 or 70 mg/kg over 3 or 5 days) resulted 
in higher early chloroquine concentrations compared with 
standard treatment with 25 mg/kg in a study by Ursing 
et al. [19]. Malaria symptoms were reported to resolve by 
day 3 in parallel with increasing chloroquine concentra-
tions. Both dosages of 50 and 70 mg/kg over 3–5 days were 
well tolerated. While there were no significant changes in 
blood pressure or heart rate, the median QTc interval was 
12–26 ms higher at expected peak concentrations than at 
day 0 (p < 0.001), which is similar to changes reported in 
adults. Other side effects included vomiting and one case of 
convulsions, which were most probably the result of malaria 
and not due to chloroquine toxicity [19]. More experience 
on the 50-mg/kg dose over 3 days in children varying in 
age between 6 months and 15 years of age is available in 
other studies from the same author [53]. Similarly, Zhao 
et al. reported that children under the age of 5 years may 
require a higher milligram/kilogram dose than adults to 
achieve the same chloroquine exposure [20]. In Fig.  2, 
WT = 50 kg, CL = 100%
WT = 70 kg, CL = 75%
WT = 70 kg, CL = 100%




















































Fig. 1  Plasma concentration–time profile in a typical adult patient 
of 50  kg with normal renal function (dotted line), 70  kg with renal 
impairment (25% reduction in clearance [CL], short dashed line), 
70 kg with normal renal function (solid line), and in an obese adult 
of 150 kg with normal renal function (long dashed line) based on the 
pharmacokinetic model from Zhao et al. [20], which was adapted for 
obese patients (i.e., 0.75 allometric increase in CL and maximized 
volumes and intercompartmental CL on values for an 80-kg indi-
vidual; see ESM for details). Two dose regimens were simulated: a 
dose regimen according to the SWAB (Dutch Working Party on Anti-
biotic Policy) guideline [69] (total 3300 mg over 5 days with 600 and 
300  mg on the first day) and b dose regimen according to Pussard 
et  al. [47] (30  mg/kg over 48  h with a maximum dose of 2400  mg 
[80 kg] for obese patients). Chloroquine concentrations are shown in 
μmol/L (left axis) and mcg/L (right axis). To compare plasma con-
centrations with whole blood concentrations, multiply by a factor of 
2.5–8 [1, 16, 17]. WT body weight
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concentration–time profiles are shown for the currently pro-
posed dose regimen for COVID-19-associated pneumonia 
in children, 55 mg/kg over 5 days (A) vs the 70-mg/kg dose 
over 5 days derived from Ursing et al. [19] (B) for children 
varying in age between 0.5 and 8 years of age based on the 
model published by Zhao et al. [20]. For children, this model 
was slightly adapted based on the predictive performance of 
the model against other reports in infants and children [19, 
48, 50, 51], for which a reduced clearance with 25% and 50% 
was inserted in children below 5 and 1 year of age, respec-
tively, on top of the allometric scaling that is already part 
of this model (see ESM). Comparable to what was seen in 
adults (Fig. 1), these concentration–time profiles show that 
the intense dose schedule proposed by Ursing et al. results 
in higher concentrations shortly after the start of therapy 
(panel B), while maximum concentrations remain similar 
compared to currently proposed dosages (panel A). Despite 
the fact that infants of 6 months of age were included in 
the original study by Ursing et al. [53], it seems that in this 
group higher concentrations are obtained with this dosing 
schedule compared with older children (Fig. 2b).
6  Special Patient Populations
In addition to how to dose chloroquine safely in children, 
as was discussed in the previous section, it is also impor-
tant to know how to dose chloroquine in other special 
patient populations such as those with renal insufficiency, 
critical illness, and obesity, and whether race might have 
an impact. Acute renal insufficiency may occur as a result 
of multi-organ failure associated with severe acute SARS-
CoV-2 infection. Therefore, it is important to consider the 
influence of renal insufficiency when using chloroquine in 
COVID-19. Given the prolonged half-life that was reported 
in patients with chronic kidney disease [49], a longer time 
to steady state and higher steady-state concentrations can be 
expected in renal insufficiency when starting the treatment 
in the acute situation. In a study in six patients with chronic 
renal failure with plasma creatinine values varying between 
1.6 and 12.7 mg/dL (or CKD-EPI between 5.3 and 68 mL/
min/1.73  m2), peak concentrations were as expected, while 
the elimination plasma half-life was prolonged. Evaluation 
of this data using the Zhao et al. model [20] showed that for 
most patients with renal impairment a reduction in clear-
ance of 25% leads to a good description of the observed 
0.5 year − 6 kg 2 year − 12 kg 4 year − 17 kg 8 year − 27 kg














































































Fig. 2  Plasma concentration–time profile in four typical children of 
0.5, 2, 4, and 8 years of age with normal renal function (solid line) or 
with renal impairment (25% reduction in clearance [CL], dashed line) 
based on the pharmacokinetic model from Zhao et  al. [20], which 
was adapted for children aged below 5 and 1  years to be in agree-
ment with observations in children in other reports [19, 50, 51] (i.e., a 
reduction in CL to 75% and 50% on top of allometric scaling (that is 
already in the model) for children below 5 and 1 year of age, respec-
tively (see ESM for details). Two dose regimens were simulated: a 
dose regimen according to the SWAB (Dutch Working Party on 
Antibiotic Policy) guideline/Dutch Children’s Formulary [69] (total 
55 mg/kg over 5 days) and b dose regimen according to Ursing et al. 
[19] (70 mg/kg over 5 days). Chloroquine concentrations are shown 
in μmol/L (left axis) and μg/L (right axis). To compare plasma con-
centrations with whole blood concentrations, multiply by a factor of 
2.5–8 [1, 16, 17]
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concentrations (see ESM). This finding seems in line with 
the fact that chloroquine is extensively distributed and for 
the most part metabolized, with renal clearance of the parent 
compound being only about one third of total clearance [7, 
30]. We believe that this 25% reduction in clearance is also 
applicable to patients with a more severe renal dysfunction 
(under 10 mL/min/1.73  m2) because the potential further 
reduction in chloroquine clearance due to severe renal insuf-
ficiency may be compensated by renal replacement therapy. 
In a study in four adults undergoing hemodialysis, chloro-
quine was dialyzed with a clearance of 58 mL/min, which 
is around 15% of the normal total body clearance [54]. In 
Fig. 1, concentration–time profiles in adult patients with 
renal insufficiency are shown for the two different dosing 
regimens, illustrating a limited influence of renal dysfunc-
tion on plasma concentrations. The inclusion in this figure 
of an (underweight) individual of 50 kg with normal renal 
function shows that underweight leads to slightly higher 
concentrations when using a fixed-dose regimen (Fig. 1a), 
compared with an individual of 70 kg with renal dysfunc-
tion. The use of the loading dose scheme of Pussard et al. 
[47] reduces the differences between individuals with and 
without renal dysfunction or underweight (Fig. 1b). This 
demonstrates that the changes in chloroquine concentra-
tions observed in patients with renal impairment are in the 
same order of magnitude as observed in a 50-kg patient with 
normal renal function (Fig. 1a). Additionally, in Fig. 2, the 
influence of renal dysfunction in children is illustrated com-
pared to children with normal renal function. This figure 
underlines the limited impact of renal impairment when the 
currently used loading dose schemes are used.
Critical illness has been widely recognized as a disease 
state that can have major impact on drug pharmacokinet-
ics [55]. Besides renal insufficiency, pro-inflammatory 
cytokines such as interleukin-6 or tumor necrosis factor 
have also been shown to influence drug clearance during sys-
temic inflammatory response by, for example, suppression of 
CYP3A4 [55, 56]. As extreme inflammation has also been 
reported in critically ill COVID-19 patients, an important 
question is what to expect with regard to chloroquine phar-
macokinetics in these patients. In a pharmacokinetic study 
by Edwards et al. in nine patients with malaria, a disease 
that is also characterized by high levels of pro-inflammatory 
cytokines [57], and ten healthy volunteers, no significant dif-
ferences in chloroquine clearance were found [52]. Moreo-
ver, the evaluation of the Zhao et al. model, which was devel-
oped in healthy adult volunteers against data from patients 
with malaria, showed that this model could also predict the 
chloroquine plasma concentrations in patients with malaria 
over the first 10 days after an intravenous dose (see ESM 
for details). Potentially, this low influence of inflammation 
can be explained by the fact that chloroquine is extensively 
metabolized by a wide variety of CYP enzymes and for a 
part cleared renally. Moreover, this paper discussed chloro-
quine dose regimens of Pussard et al. [47] and Ursing et al. 
[19] with regard to safety and efficacy in malaria. Hence, 
it seems that no major differences in pharmacokinetics in 
critically ill COVID-19 patients are to be expected, even 
though pharmacokinetic studies evaluating this influence are 
awaited. When studying the pharmacokinetics in critically ill 
patients, one should remain aware of the fact that provided 
oral chloroquine is studied, clearance and volume of dis-
tribution over bioavailability (apparent clearance [CL/F] or 
apparent volume of distribution [Vd/F]) are obtained with a 
potential influence of critical illness on clearance (or volume 
of distribution) or bioavaibility or both. Given the report that 
food may increase absorption [8], beside a (small) difference 
in clearance or volume of distribution, a difference in F may 
also be anticipated.
Regarding obese patients, doses may or may not require 
adaptation in this special population. As a general rule, this 
cannot be predicted on the basis of lipophilicity or elimina-
tion pathway alone [58, 59]. Based on the first epidemio-
logical studies on the SARS-CoV-2 virus, it appears that 
co-morbidities such as diabetes mellitus and hyperten-
sion increase the risk for development of acute respira-
tory distress syndrome [60]. Additionally, obesity has been 
described as an independent risk factor for hospitalization 
in respiratory viral infections, including coronaviruses [61]. 
Therefore, it can be expected that a relatively large portion 
of the critically ill COVID-19 patients are (morbidly) obese. 
We could not identify any studies on the effect of obesity 
on chloroquine pharmacokinetics in the available literature. 
While the pharmacokinetic model by Zhao et al. [20] iden-
tified weight as a significant covariate for pharmacokinetic 
parameters using a fixed allometric approach in data from 
(presumably normal-weight) adults and children, there is no 
information about whether this model can be extrapolated 
to obese patients. Given the fact that the typical values for 
chloroquine clearance and volume of distribution are already 
very large (59.1 L/h and 2870 L for central and 1890 L for 
peripheral volume of distribution), it is unlikely that obe-
sity significantly impacts the volume of distribution. For 
example, for propofol, which has similar pharmacokinetic 
properties to chloroquine with a very large volume of distri-
bution, high clearance, and a prolonged terminal elimination 
half-life in normal-weight patients, no increase in the vol-
ume of distribution was found in obese patients [62]. Until 
more information becomes available, it can be assumed that 
the increase in clearance is not more than an increase with 
bodyweight to the power of 0.75, which is similar to the 
increase reported when going from children to adults [20]. In 
Fig. 1, concentration–time profiles are given for a morbidly 
obese patient assuming this allometric increase in clearance, 
while the volumes of distribution were kept at values for 
an individual of 80 kg. The results of this figure illustrate 
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that in this worst-case scenario assuming increased clear-
ance values in obese patients, somewhat lower concentra-
tions are obtained in these patients for the standard-dose 
regimen that used fixed dosages. For the dosing algorithm 
of Pussard et al. [47], which we adapted for obese patients 
by capping the dose to a dose for a 80-kg individual, chlo-
roquine concentrations are comparable between morbidly 
obese and non-obese individuals with or without renal dys-
function (Fig. 1b). Alternatively, no increase in clearance in 
obese individuals can be anticipated, which would result in 
similar chloroquine concentrations as compared to the 70-kg 
adult in Fig. 1, as the dose is capped at the dose for a 80-kg 
individual. In between these scenarios, the results of a model 
in which clearance scales with lean body weight, which is 
also advocated by some as a better alternative to scaling 
with total body weight, can be found (data not shown) [63].
With regard to the influence of race, the pharmacokinetic 
properties of chloroquine do not differ in African subjects as 
compared to Caucasians [64]. However, in a population of 
Thai individuals, a two-fold lower clearance was observed 
[10] for which no real explanations could be found (see 
ESM). In the published model, also volume of distribution 
deviated from what was found in other publications. Perhaps 
some of these differences may be explained by differences in 
pharmacogenetic profiles in the Thai population compared 
with the Caucasian population with regard to CYP2D6 [65].
7  Practical Implications and Safety 
Measures for Short‑Term Use 
for COVID‑19‑Associated Pneumonia
While there is currently no general advice on the optimal 
dose for chloroquine in SARS-CoV-2, it appears that with 
dosages proposed in malaria studies or in the 5-day treat-
ment schedules currently used for COVID-19, variations in 
plasma concentrations as a result of obesity, renal dysfunc-
tion, or underweight may be limited (Fig. 1). As described 
in the previous section, this may also apply to critically ill 
patients. Regarding the influence of obesity, the concentra-
tion–time profile that can be expected assuming an increase 
in clearance in the obese population according to an 0.75 
allometric scaling function, should be seen as a worst-case 
scenario compared to no increase or an increase with lean 
body weight (see Sect. 6). When renal dysfunction occurs in 
these obese patients, the effects of these two covariates may 
even compensate for each other. With respect to renal dys-
function in a 70-kg individual, concentration–time profiles 
seem similar to that of a 50-kg individual when a fixed-dose 
regimen is given (Fig. 1a). As a result, also for renal dys-
function, no specific measures seem necessary. For children, 
there is ample information on the safety of loading doses 
from malaria studies that can be used as guidance, even 
though below the age of 6 months (Fig. 2) there is only very 
limited safety and dosing information. Given the available 
literature, children are extremely sensitive for overdose, and 
therefore misuse, dosing errors, or an accidental overdose 
may be fatal.
Less is known about what differences to expect regard-
ing oral bioavailability. Even though in most reports, the 
oral bioavailability is between 70 and 90% [6, 7], slower 
or incomplete absorption could be expected, particularly in 
critically patients. In addition, absorption may be reduced 
when taken without food resulting in lower area under the 
curve and peak concentrations [8], which may reduce the 
chance on toxic peak concentrations, although it may also 
reduce the opportunity to reach an effective plasma con-
centration. Finally, magnesium-containing antacids could 
further lower the absorption of chloroquine [9].
With the dosages demonstrated in Fig. 1, plasma con-
centrations appear to increase no higher than 1.0 or 1.5 
μmol/L (Fig. 1), which is below the concentration of 2.5 
μmol/L that was associated with toxicity during long-term 
use for rheumatoid arthritis [37], recovery of a case after 
massive overdose [34], and reversible toxicity with intrave-
nous dosing [7]. As information on efficacy against COVID-
19-associated pneumonia is not yet available, an important 
question is what toxicity would be acceptable. With the dos-
ages proposed for malaria or COVID-19, expected toxicity 
is mainly related to QTc prolongation and widening of the 
QRS complex. Chloroquine cardiotoxicity seems specifi-
cally relevant for COVID-19, since an acute myocarditis was 
recently reported as a possible complication of COVID-19 
[66]. Particularly in the case of co-treatment with other QTc-
prolonging agents such as amiodarone, macrolide antibiot-
ics (such as azithromycin), ondansetron, and many others 
[67], before the start of chloroquine treatment an electro-
cardiogram should be performed and QTc time measured 
and repeated after the start of chloroquine treatment and 
other potentially QTc-prolonging agents on a daily basis. In 
addition, chloroquine could lead to hypoglycemia [9], for 
which additional monitoring needs to be considered. In those 
cases where toxicity would occur at therapeutic doses, we 
can learn from reports on chloroquine overdose, where it 
was shown that even after massive overdoses toxic effects 
beyond 24 h are rare [34], which may be explained by rapid 
redistribution to tissues despite the fact that the elimination 
half-life is about 2 weeks.
8  Conclusions
While promising announcements from in vitro studies and 
a preliminary clinical report may promote the use of chlo-
roquine for SARS-CoV-2 infection, controlled clinical trials 
are still lacking. This also applies to hydroxychloroquine, 
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which is referred to as less toxic than chloroquine and per-
haps more effective against SARS-CoV-2 [1], with others 
reporting less in vitro activity [68]. The lack of reliable 
information on what concentrations to aim for or doses to 
use for COVID-19-associated pneumonia implies that for 
both adults and children doses should be considered that 
have been proven to be both effective and safe in malaria 
and that result in early high concentrations. In doses used 
for malaria, tolerability of these dosages is good provided 
QTc measurements before and after the start of treatment are 
performed, especially when chloroquine is given together 
with other drugs that can potentially prolong QTc or with 
cardiac involvement of COVID-19. Renal dysfunction or 
morbid obesity may introduce some variability even though 
their influence seems acceptable in relation to variability for 
instance resulting from underweight. Even though bioavail-
ability is good, when given in critically ill patients, reduced 
absorption may be expected, particularly when enteral feed-
ing is hampered because food may increase the absorption. 
However, clinical experience has shown that chloroquine has 
a very narrow margin of safety. The adult therapeutic dos-
age for malaria is 10 mg/kg whereas a single dose of 30 mg/
kg may be lethal. Finally, although infrequent, poisoning in 
children is extremely dangerous because children are par-
ticularly sensitive to chloroquine toxicity with one to two 
tablets being potentially fatal. With that in mind, it seems 
that if this drug is to be more widely used, its distribution 
must be strictly controlled and patients should be warned 
to keep the drugs out of reach from others, in particular 
(young) children.
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